Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | APOBEC3G | Q9HC16 | 6/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26834160 | 0.86 | HSD17B10 (0.58) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL1544445 | 0.81 | HSD17B10 (0.74) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL13984119 | 0.81 | KDM4E (0.57) | ALDH1A1APOBEC3GHSD17B10KDM4EHPGD | |
| SCHEMBL8978607 | 0.80 | KDM4E (0.71) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL8762409 | 0.79 | APOBEC3G (0.63) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL2893202 | 0.78 | HSD17B10 (0.59) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL9222389 | 0.76 | HSD17B10 (0.61) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL8978546 | 0.75 | KDM4E (0.68) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL2316369 | 0.74 | ALDH1A1 (0.74) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E | |
| SCHEMBL919250 | 0.74 | HSD17B10 (0.73) | ALDH1A1APOBEC3GHSD17B10LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | DRD3, DRD2, SLC6A3 | ALDH1A1 941/4885APOBEC3G 2192/4885HSD17B10 1505/4885 |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | ALDH1A1 1261/4885APOBEC3G 3155/4885HSD17B10 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.